These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12208487)

  • 1. Effects of various fibrates on serum alkaline phosphatase activity.
    Ganotakis E; Tsimihodimos V; Bairaktari E; Rizos E; Athyros V; Seferiades C; Elisaf M
    Atherosclerosis; 2002 Nov; 165(1):187-8. PubMed ID: 12208487
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L
    Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibrate-induced increase in blood urea and creatinine.
    Lipscombe J; Bargman JM
    Nephrol Dial Transplant; 2001 Jul; 16(7):1515. PubMed ID: 11427661
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
    Abourbih S; Filion KB; Joseph L; Schiffrin EL; Rinfret S; Poirier P; Pilote L; Genest J; Eisenberg MJ
    Am J Med; 2009 Oct; 122(10):962.e1-8. PubMed ID: 19698935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin-fibrate combinations in patients with combined hyperlipedemia.
    Athyros VG; Papageorgiou AA; Kontopoulos AG
    Atherosclerosis; 2001 Mar; 155(1):263-4. PubMed ID: 11293392
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipid profiles on fibric-acid derivatives.
    Capps NE
    Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
    Dick TB; Marples J; Ledermann HM; Whittington J
    Curr Med Res Opin; 1981; 7(8):489-502. PubMed ID: 7030635
    [No Abstract]   [Full Text] [Related]  

  • 9. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
    Broeders N; Knoop C; Antoine M; Tielemans C; Abramowicz D
    Nephrol Dial Transplant; 2000 Dec; 15(12):1993-9. PubMed ID: 11096145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G
    Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interactions with fibric acids.
    Lozada A; Dujovne CA
    Pharmacol Ther; 1994 Aug; 63(2):163-76. PubMed ID: 7809177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofibrate and lipid profile.
    Chandler HA; Batchelor AJ
    Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E; Kostoula A; Elisaf M; Mikhailidis DP
    Angiology; 2002; 53(3):273-7. PubMed ID: 12025914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP; Jagroon IA
    Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract]   [Full Text] [Related]  

  • 15. Fibrate treatment can increase serum creatinine levels.
    Tsimihodimos V; Kakafika A; Elisaf M
    Nephrol Dial Transplant; 2001 Jun; 16(6):1301. PubMed ID: 11390746
    [No Abstract]   [Full Text] [Related]  

  • 16. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
    Harlé JR; Toussirot E; Disdier P; Drancourt M; Weiller PJ
    Rev Med Interne; 1990; 11(4):336. PubMed ID: 2096444
    [No Abstract]   [Full Text] [Related]  

  • 17. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
    Maiguma T; Fujisaki K; Itoh Y; Makino K; Teshima D; Takahashi-Yanaga F; Sasaguri T; Oishi R
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):289-96. PubMed ID: 12644902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
    Masnatta LD; Cuniberti LA; Rey RH; Werba JP
    J Chromatogr B Biomed Appl; 1996 Dec; 687(2):437-42. PubMed ID: 9017468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
    Rizzo M; Berneis K
    Curr Med Res Opin; 2007 May; 23(5):1103-11. PubMed ID: 17519077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.
    Walli AK; Seidel D
    Res Exp Med (Berl); 1981; 179(2):153-61. PubMed ID: 7280363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.